FSTL3 and breast carcinoma: All in all, together with the findings that FLRG contributes to tumor cell proliferation through antagonizing activin effects [17], we assume that the increased activin A expression reported in breast carcinoma is counteracted by an increased FLRG expression that prevents activin from binding its receptors and thus reducing smad signaling and activin anti-proliferative effects.